Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic designed to treat diabetic macular edema (DME) and related eye conditions. …
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results Read More